Tag: Moolec Science SA

Moolec Science SA (NASDAQ:MLEC) (The Company or Moolec), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the BCA) with Bioceres Group Limited (Bioceres Group) and other related entities in an all-stock transaction (the Business Combination).

Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC (“Nutrecon”), and Gentle Technologies Corp (“Gentle Tech”, and together with Bioceres Group and Nutrecon, the “Contributed Entities”), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.

Federico Trucco, Bioceres Group’s board member and CEO of Bioceres Crop Solutions Corp commented: “The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?” He then finished: “Moolec’s recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive ‘cradle-to-cradle’ approach.”

Juan Sartori, Founder and Chairman of Union Group remarked: “This is not just a strategic alignment of businesses, it’s the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I’m proud to support this vision and the exceptional teams bringing it to life.”

Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec’s new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.

Alejandro Antalich, Chairman of Synbio Powerlabs® added: “This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it.”

As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.

José López Lecube, CFO and Director of Moolec commented: “This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec’s new and more diversified business.”

Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec’s Extraordinary General Meeting (“EGM”) to be held on April 22, 2025.

Key highlights:
Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.

Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.

Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.

Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.

Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.

Timing and Approvals
The Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec’s reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec’s shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec’s current shareholders, the Company expects strong shareholder support for the Business Combination approval.

The Business Combination will be consummated through an equity exchange. Bioceres Group’s shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.

The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec’s current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.

Description of Contributed Entities and Assets
The Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.

Bioceres Group
Bioceres Crop Solutions Corp. (NASDAQ: BIOX)
Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.

Bioceres Tech Services (Agrality® & Inmet)

Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality’s key assets include advanced seed production facilities, enabling high-quality seed development and production.

Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.

Nutrecon (Synbio Powerlabs®)
Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization (“RTO”) and a Contract Development and Manufacturing Organization (“CDMO”). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.

Gentle Tech (G-FAS & Gentle Farming)
A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).

Forward Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contact Information
Press & Media: comms@moolecscience.com
Investor Relations: ir@moolecscience.com

SOURCE: Moolec Science SA

Related Documents:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf

Moolec Science SA (NASDAQ:MLEC) (the Company), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) has completed its Regulatory Status Review (RSR) for the Company’s genetically engineered (GE) peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here.

“With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea,” said Gastón Paladini, CEO and Co-Founder of Moolec. “We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone underscores our leadership in the landscape with tangible, science-backed results.”

Moolec’s genetically engineered peas produce high yields of bovine myoglobin, a protein that boosts iron content, making it an ideal alternative for consumers seeking plant-based sources of iron. This product has the potential to revolutionize both the food ingredient market and the $65 billion pea industry by offering a nutritious, iron-rich alternative to traditional meat products.

Amit Dhingra, Chief Science Officer for the Company, stated, “The USDA-APHIS Regulatory Status Review for pea marks a significant milestone for Moolec. As the first review for GE pea, it represents a historic development. It validates Moolec’s strategic approach and exemplifies our commitment advancing sustainable food production through science and innovation. This approval is a critical step toward enhancing global food supply and meeting the growing demand for innovative, nutritious food solutions for the world.”

This approval not only showcases Moolec’s innovation in Molecular Farming but also highlights the company’s commitment to meeting the highest regulatory and safety standards. Moolec has also developed an Identity Preservation Program to ensure sustainable farming practices, promote stewardship for its crops and product quality for partners, clients and consumers alike.

According to USDA-APHIS regulation found at 7 CFR part 340, developers may submit a request for a RSR when they believe a GE plant is not subject to the regulation. APHIS reviews the GE plant and considers whether it might pose an increased plant pest risk compared to its non-GE comparator. If APHIS does not identify a greater pest risk relative to the comparator, the GE plant is not subject to this regulation. Regulation 7 CFR part 340 governs the importation, interstate movement, and the environmental release of certain organisms that have been modified or produced by genetic engineering.

The USDA-APHIS review process is a critical component of ensuring that genetically engineered crops can be grown safely, and this approval opens the floor for expanded field trials, seed scaling, and eventual commercialization. With increasing interest in science-based ingredients, this approval positions the company to lead a new wave of innovation in the food and agriculture sectors.

About Moolec Science SA
Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins for the good of the planet. Moolec’s technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company’s Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.

Forward-Looking Statements
This publication contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this publication, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this publication will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contact Information
Press & Media
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

Related Files
Moolec Has Received USDA Approval For The First Genetically Modified Pea In History

SOURCE: Moolec Science

Moolec Science SA (NASDAQ:MLEC) (The Company, Moolec), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024.

GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign located in Idaho consists of 600 planted acres of genetically modified safflower, mainly for commercial purposes. As a result of the harvest, Moolec is expecting to produce between 300 to 400 tons of safflower seeds that contain high levels of GLA. To allocate most of the upcoming GLASO™ production, Moolec has secured an offtake agreement with a major global CPG company, targeting the US market in 2025. Following a successful and rigorous audit from Moolec’s CPG customer, production is set to begin in late 2024.

The Company is also developing a broader commercial strategy to reach larger markets and clients. Moolec’s GLASO™ product contains almost 3 times more GLA than conventional sources such as borage and primrose oil, making it the most concentrated GLA oil available on the market.

Piggy Sooy™ (porcine myoglobin in soybean seeds) field trials are being carried out in 3 different US locations: Ohio, Missouri and Iowa. Main purposes for the campaign are product development (sampling), seed increase and gathering of environmental and regulatory data to continue Moolec’s US-FDA approval pathway. The Team also projects a remarkable first open field performance for its bioengineered soybean Piggy Sooy™ after recent approval for cultivation from USDA-APHIS. This has set an unprecedented milestone in biotechnology last April, with Moolec becoming the first Molecular Farming company to obtain this kind of clearance for food crops growing animal proteins in US territory.

Chief Technology Officer and Co-Founder Martín Salinas stated: “Our commitment to scaling Moolec’s Molecular Farming Technology is demonstrated by our GLASO™ campaign and the field trials of Piggy Sooy™. These efforts not only reinforce our position as pioneers in the industry but also lay the foundation for sustainable solutions in agriculture and biotechnology.” He then finished by remarking: “One acre of Piggy Sooy™ could potentially produce pork meat proteins equivalent to 10 pigs, reducing water footprint, land usage and CO2 emissions. This is a clear demonstration on how we promote environmental improvements throughout all our operations. Our aim is to heal the meat production system.”

Contact Information
Press & Media
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

Related Files
Moolec Confirms US Harvest And Promising Yields For Plant-Grown Products GLASO™ And Piggy Sooy™ In October – 2024.09.05

SOURCE: Moolec Science

Moolec Science SA (NASDAQ:MLEC) (the Company), a Molecular Farming ingredient company, announced today the signing of an offtake agreement with one of the largest global consumer packaged goods and pet food companies for the use of Moolec’s patented science-based GLA Safflower Oil product, GLASO™ (the Agreement). This initial offtake agreement has a term of three years and establishes commercial conditions for the delivery of GLASO™ in US territory with an initial estimated volume of 50 tons for 2025.

GLASO™ is a nutritional omega 6 oil obtained from bioengineered safflower seeds. With high-GLA (gamma linolenic acid) concentration, Moolec’s product contains almost 3 times more GLA than conventional sources such as borage and primrose oil, making it the most concentrated GLA oil available on the market. GLA is widely recognized for its health-promoting attributes and is primarily embraced as a valuable addition to various diets in the form of a dietary supplement, functional food, cosmetics, and animal nutrition such as pet food, main application targeted by this offtake Agreement.

Moolec Science also announces that it has signed binding agreements with farmers to cultivate safflower as well as with an industrial partner to secure state of the art downstream capacity. Both agreements are paramount to ensure a fully-controlled and traceable supply chain for GLASO™.

“We are thrilled to announce this significant supply agreement for our GLASO™ nutritional oil product. This milestone, coupled with our new partnership for industrial toll processing, marks a pivotal step in our mission to deliver high-quality, innovative health solutions to our customers worldwide. It underscores our commitment to quickly scaling from small to large volume production and meeting the growing demand for sustainable nutritional ingredients,” said Martín Salinas, Chief Technology Officer & Co-Founder of the Company.

Moolec’s Molecular Farming Platform encompasses revolutionary technology enabling the production of high-quality ingredients, such as nutritional oils and proteins, in plants. The company leads the industry in demonstrating that its technology can be scaled efficiently, affordably, and sustainably. This allows for ingredients to be designed that will offer significant cost-in-use reductions compared to traditional and cellular agricultural methods.

Gastón Paladini, CEO & Co-Founder of Moolec, concluded: “We are very excited about this team accomplishment. It is a concrete and important step in Moolec’s path to commercialize our flagship technology. Going forward, we will intensify our business development and commercialization efforts with major participants in the manufacturing and ingredients business.”

Note to reader: Due to the competitive nature of these agreements, and the fact that Moolec Science is in continuing negotiations for further contracts, disclosure over third parties and price will not be made at this time. Moolec Science will keep the market informed with updates on its annual report that provides a comprehensive overview of the company’s business and financial condition.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contact Information
Press & Media
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

Related Files
Moolec Signs an Offtake Agreement With Major Global CPG Company to Hit the US Market in 2025 – 2024.07.15

SOURCE: Moolec Science

Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.

Moolec Science Logo

The main highlights of Moolec’s business update are as follows:

• Piggy Sooy™ Product | Soybean Platform: Moolec’s patented soybean product received USDA-APHIS Regulatory Status Review approval in April 2024.
• Safflower Platform: GLASO™ planting campaign progressing as expected. Two US Patents granted for production of chymosin in safflower seeds (SPC2) extended exclusive technology protection until 2041.
• Financial highlight: Normalized revenues and other income (Ex-IAS 29) up ~$1.3M YoY given consolidation of soy-protein ingredient business. R&D, Admin and other expenses of $2.3M increased 68% YoY mainly due to non-cash items. Operational cash utilization this quarter of ~$2.6M includes ~$1.4M allocated to lower accounts payable.

“These past few months mark a significant milestone in Moolec’s journey, showcasing our relentless pursuit to deliver results. Our progress on Piggy Sooy™ with the USDA-APHIS regulatory RSR approval, in addition to the starting of our GLASO™ commercial production streams are pivotal achievements that underscore our unwavering commitment to nutritional and sustainable solutions. I am thrilled to witness just the beginning of the fruits of our labor and am grateful for the continued and unwavering dedication of our team,” expressed Gastón Paladini, Chief Executive Officer and Co-Founder of Moolec Science.

José López Lecube, Chief Financial Officer for the company, stated, “We are very pleased with our team’s consistent milestones delivery as we are addressing meaningful market opportunities. We remain confident in our disciplined approach to spending while preserving an adequate cash position and balance sheet to fund the business. I want to extend my congratulations to our team for the exceptional USDA-APHIS regulatory RSR approval, a major achievement for our long-term business plan execution.”

For a full version of Moolec’s first quarter Fiscal Year 2024 Business Update, click here.

Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar. To access the call, please use the following information:

• Date: Thursday, May 30, 2024
• Time: 8:30 a.m. Eastern Time (U.S. and Canada)
• Link to join the webinar: https://icrinc.zoom.us/j/91289208286?pwd=Rm9SS0hlRzN6d01WdU1od3IrZTBxdz09
• One tap mobile: +13017158592,,91289208286#,,,,*888246# US
• Dial In: +1 301 715 8592 | Webinar ID: 912 8920 8286, Passcode: 888246
• International numbers available: https://icrinc.zoom.us/u/aid5QyFr4

Please connect 5 minutes prior to the start time to register and join.

A recording of the call and the pdf version of the presentation will be available after the conclusion of the live event via Moolec’s Investor Relations website.

About Moolec Science SA
Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins, for good and for all. Moolec’s technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company’s Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Moolec’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contact Information
Catalina Jones
Chief of Staff & Sustainability
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

Related Files
Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update – May 30, 2024

SOURCE: Moolec Science

Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the second quarter of Fiscal Year 2024 ended December 31, 2023.

Moolec Logo
Moolec Science Logo

The main highlights of Moolec’s business update are as follows:

• SOOY1 | Piggy Sooy™ Platform: Third generation (T3) soybean seed propagation has started, and fourth generation (T4) seeds are expected to be harvested in April 2024. A molecular analysis reveals that the current T3 soybean population contains a stable number of porcine myoglobin gene copies consistent with a population that is not segregating.
• PEEA1: Scientific team confirms the presence of bovine myoglobin gene in pea seeds and the gene’s stable inheritance across plant generations.
• YEEA1: Moolec´s prototyping platform includes a novel yeast strain that is being developed as a dietary supplement and food ingredient, and Moolec has begun the first of several pre-submission consultations with US-FDA.
• Product Marketing: The next generation of textured plant-protein prototypes produced at Moolec’s industrial and commercial R&D center were presented to the public in Gulfood 2024.
• Financial highlight: Capital Raise of ~$30M with $10M in cash and ~$20M in kind contributions materialized in October 2023 with strategic investors through a convertible note followed by an additional ~$1M raised with farmers in December 2023. Revenues and other income (Ex-IAS 29) of ~$1.7M slightly down QoQ. R&D, Admin and other Expenses in line with historical track record of cost efficiency. Operational cash utilization of ~$4M includes ~$2.7M allocated to lower accounts payable.

“This quarter has been a testament to the dedication and hard work of our team. We have made steady progress in our research and development efforts as well as product development. I am incredibly proud of our team’s delivery and execution. Thank you to the Moolers, and to our partners for their continued support,” stated Gastón Paladini, Chief Executive Officer and Co-Founder of Moolec Science.

“Our financial position reflects our commitment on multiple fronts. The strategic partnerships we have formed, most recently with farmers, will be instrumental not only in our funding health, but also contribute to support Moolec’s product growth and commercialization in the near future,” declared José López Lecube, Chief Financial Officer for the company. He then continued by saying: “As we move forward, we remain focused on maintaining a healthy financial position and are confident in our ability to navigate the next stages of our growth.”

Conference Call

Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar.

To access the call, please use the following information:

• Date: Wednesday, March 13, 2024
• Time: 08:30 AM Eastern Time (US and Canada)
• Link to join the webinar: https://icrinc.zoom.us/j/92375922161?pwd=Qmt6NzdVUGNWaEhTT1NDOHU3Tjlydz09
• One tap mobile: +13017158592,,92375922161#,,,,*888246# US
• Dial In: +1 301 715 8592 US | Webinar ID: 923 7592 2161, Passcode: 888246
• International numbers available: https://icrinc.zoom.us/u/acVKYeTJwM

Please connect 5 minutes prior to the start time to register and join.

A recording of the call and the pdf version of the presentation will be available after the conclusion of the live event via Moolec’s Investor Relations website.

About Moolec Science SA
Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal-based food, for good and for all. Moolec’s technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybean and safflower. Recently, it acquired plant-based ingredient capabilities to consolidate Molecular Farming Technology. Moolec has a growing international patent portfolio (26, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Moolec’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contact Information
Catalina Jones
Chief of Staff & Sustainability
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

Michael Bowen
ICR, LLC
moolecir@icrinc.com

Related Files
Moolec Science – Business Update Q2FY2024_Final

SOURCE: Moolec Science

View the original press release on newswire.com.

Moolec Science SA (NASDAQ:MLEC), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the first quarter of Fiscal Year 2024 ended September 30, 2023.

The main highlights of Moolec’s business update are as follows:

• GLASO: Moolec harvested 35 hectares with a yield of 1.8 tons per hectare. Currently, the company is preparing for the next campaign getting closer to commercialization.
• SOOY1 | Piggy SooyTM Platform: Moolec’s soybeans have been propagated to the next generation (T3) and T3 seed analyses confirmed high levels of porcine myoglobin protein for a second consecutive generation.
• Moolabs: Moolec’s self-owned Molecular Biology Lab at Texas A&M University’s Bioscience Business Accelerator has been successfully set¬up and is fully operational.
• Financial highlight: Revenue increased 92% QoQ to $1.74 million given full quarter consolidation of acquired business and higher volume and prices. Lower COGS impact given stable soy origination and more favorable local market conditions. Low cash utilization of ~$1.74 million remains in line with historical track record.

“We are pleased to report a solid business update. I commend our team’s efforts to succeed in all facets of R&D. Moreover, we are encouraged by the progress made on the scientific development of products, which address an attractive opportunity to bring new integral and sustainable solutions to the food market and beyond,” stated Gaston Paladini, Chief Executive Officer and co-founder of Moolec Science.

“We are happy to share the financial progress for the first quarter of fiscal year 2024,” said José Lopez Lecube, Chief Financial Officer of Moolec Science. He then continued by saying, “While we focus our resources on the scientific front, we are also pleased to see the progress in our ‘R&D and Commercial Center’ generating revenues and providing a centralized location for pilot runs of our promising portfolio of R&D projects.”

For a full version of Moolec’s first quarter Fiscal Year 2024 Business Update, click here.

Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar.

For a full version of Moolec’s first quarter Fiscal Year 2024 Business Update, click here.

Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar.

To access the call, please use the following information:– Date: Thursday December 14, 2023- Time: 08:30 a.m. ET- Link to join the webinar: https://icrinc.zoom.us/j/98069578649?pwd=bHNaQnI0RXRUZ2l0RFR2VU8wQnZidz09- One tap mobile: +13017158592,,98069578649#,,,,*881714# US- Dial In: +1 301 715 8592 US | Webinar ID: 980 6957 8649, Passcode: 881714- International numbers available:https://icrinc.zoom.us/u/abCKbnCHri

Please connect 5 minutes prior to the start time to register and join.

A recording of the call and the pdf version of the presentation will be available approximately two hours after the conclusion of the live event via Moolec’s Investor Relations website.

About Moolec Science SAMoolec is a science-based ingredient company leader in the use of Molecular Farming technology for food. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal-based food, for good and for all. Moolec’s technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybean and safflower. Recently, it acquired plant-based ingredient capabilities to consolidate Molecular Farming Technology. Moolec has a growing international patent portfolio (26, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America.

Forward-Looking StatementsThis press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Moolec’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contacts:Press & Media inquiries | Catalina Jones: comms@moolecscience.comInvestor Relations inquiries: ir@moolecscience.com | Michael Bowen, ICR, LLC: MoolecIR@icrinc.com

Contact InformationCatalina JonesChief of Staff & Sustainabilitycomms@moolecscience.com

Investor Relationsir@moolecscience.com

Michael BowenICR, LLCmoolecir@icrinc.com

Related FilesMoolec Science Presents First Quarter Fiscal Year 2024 Business Update.pdf

View the original press release on newswire.com.

Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, today reported its Business Update for the fourth quarter of Fiscal Year 2023 ended June 30, 2023.

The main highlights of the Company’s business update are as follows:

• Piggy Sooy(TM): introducing a soybean platform that can produce high amounts of pork protein.
• The animal protein reached high expression levels of up to 26.6% of total soluble protein in soy seeds, 4x higher than initially projected by the Company.
• Completed Regulatory Status Review submission from USDA-APHIS and engaged in pre-submission discussions with FDA.
• New patent was successfully filed.
• Moolabs: New Moolec’s Molecular Biology Lab in Texas A&M University Bioscience Business Accelerator.
• GLASO: 2023 safflower campaign finished with ~50% above average crop yields.
• Capital Raise: ~$30 million from strategic investors in cash and in-kind contributions.

“Looking back, I am incredibly proud of what Moolec has accomplished. We set ambitious goals, and our unwavering commitment to innovation and excellence has allowed us to not only meet but exceed our objectives. Our team’s relentless dedication and innovations achieved unprecedented scientific results,” stated Gastón Paladini, Chief Executive Officer and Co-Founder of Moolec Science.

“This year, Moolec achieved important milestones that not only reflect our technological ability but also our investment backing. In addition to the $10 million raised during Fiscal Year 2023, we were able to commit $30 million from strategic investors in a challenging financial market environment. These commitments will drive Moolec´s business model forward through additional liquidity and enhanced capabilities,” said José López Lecube, Chief Financial Officer and Director of Moolec Science. He added, “Our sources of financial support and funding avenues are adequate and work to support our commitment to innovate in the food industry.”

For a full version of Moolec’s fourth quarter Fiscal Year 2023 Business Update, click here. https://pr.report/kLEIeFQN 

Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar.

To access the call, please use the following information:
– Date: Monday October 23, 2023- Time: 09:00 am ET
– Link to join the webinar: https://us06web.zoom.us/j/84198066199
– Dial In: +1 507 473 4847 US | Webinar ID: 841 9806 6199
– International numbers available: https://us06web.zoom.us/u/kbOMXArmP

Please connect 5 minutes prior to the start time to register and join.

A replay and the pdf version of the presentation will be available approximately two hours after the conclusion of the live event via the company’s Investor Relations website.

About Moolec Science SA
Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal-based food, for good and for all. Moolec’s technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybean and safflower. Recently, it acquired plant-based ingredient capabilities to consolidate Molecular Farming Technology. Moolec has a growing international patent portfolio (25, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Moolec’s Annual Report on Form 20 – Filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contact Information
Catalina Jones, Chief of Staff & Sustainability, comms@moolecscience.com
Martín Taraciuk, Investor Relations, ir@moolecscience.com
Michael Bowen, ICR, LLC moolecir@icrinc.com